Evotec Signs Agreement with DiscoveRx Corporation to Support High Throughput Screening Services
Evotec AG and DiscoveRx Corporation announced a co-marketing agreement for the screening of GPCR’s and other targets. Under the terms of the agreement, Evotec will have access to DiscoveRx’s PathHunter™ and cAMPHunter™ cell lines and proprietary EFC chemiluminescent detection technology for use during hit identification and optimization projects performed for Evotec customers, using the Company’s proprietary high throughput screening platform.
Evotec’s Executive Vice President, Business Development, Dr Mark Ashton commented: “We are constantly seeking opportunities to further enhance our Discovery Alliance Business (DAB). For our customers, this agreement means that DiscoveRx’s innovative assay portfolio of more than 300 cell based GPCR assays can be accessed in conjunction with the first-class high throughput screening set-up at Evotec. This will provide significant value to our screening partners, specifically in the area of GPCR screening.”
Other news from the department business & finance

Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
JASCO’s New European Headquarter’s Grand Opening Concludes its 50th Anniversary Celebration in 2008
